Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 7/20 | 0.43 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.33 |
| ▸ | LPL | P06858 | 1/20 | 0.33 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24529384 | 1.00 | HCRTR2 (0.43) | HCRTR2LIPGLPLAAK1 | |
| SCHEMBL27180893 | 1.00 | HCRTR2 (0.43) | HCRTR2LIPGLPLAAK1 | |
| SCHEMBL27180730 | 0.83 | HCRTR2 (0.48) | HCRTR2 | |
| SCHEMBL24529397 | 0.83 | HCRTR2 (0.48) | HCRTR2 | |
| SCHEMBL27180728 | 0.83 | HCRTR2 (0.48) | HCRTR2 | |
| SCHEMBL24529385 | 0.81 | LIPG (0.43) | LIPGLPL | |
| SCHEMBL27179468 | 0.78 | LIPG (0.42) | LIPGLPLAAK1 | |
| SCHEMBL27179471 | 0.78 | LIPG (0.42) | LIPGLPLAAK1 | |
| SCHEMBL24387204 | 0.75 | AAK1 (0.41) | LIPGLPLAAK1 | |
| SCHEMBL24529437 | 0.71 | HCRTR2 (0.51) | HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4262788-B1 | UREA OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2026-01-21 | — | — | EP | disclosed |
| US-20240101555-A1 | UREA OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2024-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240101555-A1 | UREA OREXIN RECEPTOR AGONISTS | HCRTR1, HCRTR2, UTS2R | HCRTR2 2/4885LIPG 4180/4885LPL 4075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.